These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28137826)

  • 1. Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity.
    Bhatt S; Parvin S; Zhang Y; Cho HM; Kunkalla K; Vega F; Timmerman JM; Shin SU; Rosenblatt JD; Lossos IS
    Blood; 2017 Apr; 129(16):2246-2256. PubMed ID: 28137826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What signals are generated by anti-CD20 antibody therapy?
    Bonavida B
    Curr Hematol Malig Rep; 2006 Dec; 1(4):205-13. PubMed ID: 20425315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
    Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
    Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
    Winiarska M; Bojarczuk K; Pyrzynska B; Bil J; Siernicka M; Dwojak M; Bobrowicz M; Miazek N; Zapala P; Zagozdzon A; Krol M; Syta A; Podszywalow-Bartnicka P; Pilch Z; Dabrowska-Iwanicka A; Juszczynski P; Efremov DG; Slabicki M; Zenz T; Le Roy A; Olive D; Rygiel TP; Leusen JH; Golab J
    MAbs; 2014; 6(5):1300-13. PubMed ID: 25517315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulation of the cell survival/anti-apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization.
    Vega MI; Martínez-Paniagua M; Huerta-Yepez S; González-Bonilla C; Uematsu N; Bonavida B
    Int J Oncol; 2009 Dec; 35(6):1289-96. PubMed ID: 19885551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.
    Rosario M; Liu B; Kong L; Collins LI; Schneider SE; Chen X; Han K; Jeng EK; Rhode PR; Leong JW; Schappe T; Jewell BA; Keppel CR; Shah K; Hess B; Romee R; Piwnica-Worms DR; Cashen AF; Bartlett NL; Wong HC; Fehniger TA
    Clin Cancer Res; 2016 Feb; 22(3):596-608. PubMed ID: 26423796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties.
    Nishida M; Uematsu N; Kobayashi H; Matsunaga Y; Ishida S; Takata M; Niwa O; Padlan EA; Newman R
    Int J Oncol; 2011 Feb; 38(2):335-44. PubMed ID: 21152859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
    Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
    Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and biological characterization of an anti-CD20 biosimilar candidate antibody: a case study.
    Dorvignit D; Palacios JL; Merino M; Hernández T; Sosa K; Casaco A; López-Requena A; Mateo de Acosta C
    MAbs; 2012; 4(4):488-96. PubMed ID: 22647435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a novel humanized anti-CD20 antibody with potent anti-tumor activity against non-Hodgkin's lymphoma.
    Zhang H; Song L; Ye H; Hu L; Liang W; Liu D
    Cell Physiol Biochem; 2013; 32(3):645-54. PubMed ID: 24022075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.
    Bobrowicz M; Dwojak M; Pyrzynska B; Stachura J; Muchowicz A; Berthel E; Dalla-Venezia N; Kozikowski M; Siernicka M; Miazek N; Zapala P; Domagala A; Bojarczuk K; Malenda A; Barankiewicz J; Graczyk-Jarzynka A; Zagozdzon A; Gabrysiak M; Diaz JJ; Karp M; Lech-Maranda E; Firczuk M; Giannopoulos K; Efremov DG; Laurenti L; Baatout D; Frenzel L; Malinowska A; Slabicki M; Zenz T; Zerrouqi A; Golab J; Winiarska M
    Blood; 2017 Oct; 130(14):1628-1638. PubMed ID: 28830887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
    Mössner E; Brünker P; Moser S; Püntener U; Schmidt C; Herter S; Grau R; Gerdes C; Nopora A; van Puijenbroek E; Ferrara C; Sondermann P; Jäger C; Strein P; Fertig G; Friess T; Schüll C; Bauer S; Dal Porto J; Del Nagro C; Dabbagh K; Dyer MJ; Poppema S; Klein C; Umaña P
    Blood; 2010 Jun; 115(22):4393-402. PubMed ID: 20194898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma.
    Bhatt S; Matthews J; Parvin S; Sarosiek KA; Zhao D; Jiang X; Isik E; Letai A; Lossos IS
    Blood; 2015 Sep; 126(13):1555-64. PubMed ID: 26194763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells.
    Müller T; Uherek C; Maki G; Chow KU; Schimpf A; Klingemann HG; Tonn T; Wels WS
    Cancer Immunol Immunother; 2008 Mar; 57(3):411-23. PubMed ID: 17717662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.
    Manches O; Lui G; Chaperot L; Gressin R; Molens JP; Jacob MC; Sotto JJ; Leroux D; Bensa JC; Plumas J
    Blood; 2003 Feb; 101(3):949-54. PubMed ID: 12393572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice.
    Chu Y; Hochberg J; Yahr A; Ayello J; van de Ven C; Barth M; Czuczman M; Cairo MS
    Cancer Immunol Res; 2015 Apr; 3(4):333-44. PubMed ID: 25492700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma.
    Ansell SM; Witzig TE; Kurtin PJ; Sloan JA; Jelinek DF; Howell KG; Markovic SN; Habermann TM; Klee GG; Atherton PJ; Erlichman C
    Blood; 2002 Jan; 99(1):67-74. PubMed ID: 11756154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells.
    Zheng Y; Yu K; Du J; Jiang L; Zhang S; Han Y; Yu P; Tan Y
    J Exp Clin Cancer Res; 2010 Sep; 29(1):121. PubMed ID: 20815894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eradication of non-Hodgkin lymphoma through the induction of tumor-specific T-cell immunity by CD20-Flex BiFP.
    Zhao L; Tong Q; Qian W; Li B; Zhang D; Fu T; Duan S; Zhang X; Zhao J; Dai J; Wang H; Hou S; Guo Y
    Blood; 2013 Dec; 122(26):4230-6. PubMed ID: 24178967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.